|
|
|
|
|
|
|
|
On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer
(Norgestrel (INN, USAN, BAN, JAN) (brand names Logynon, Nordette, Eugynon, Microgynon, Ovran, Ovranette, Trinordiol, numerous others) is a steroidal progestin that has been used in hormonal contraceptives. It is a mixture of two stereoisomers, dextronorgestrel (CAS# 797-64-8 ) and levonorgestrel (CAS# 797-63-7 ).)
To the Editor:
In their recent article in Journal of Clinical Oncology, Eeles et al1
discuss the adjuvant hormone-replacement therapy (AHT) trial, a
randomized trial of 150 patients with ovarian cancer, which
included patients across different epithelial
cancer histologies and stages who, as a result, were expected to have
significantly
different outcomes, independent of AHT
intervention. The planned duration of replacement as per the protocol
was 5 years,
but patients stayed on treatment for an average of
1.14 years. Most women were postmenopausal or perimenopausal.
Fifty-three
of the 72 patients who received therapy in the
treatment arm had an estrogen-only preparation, whereas 19 patients
received
estrogens combined with norgestrel. Doses actually
received are not given (suggested doses are listed in the protocol
presented
in the appendix), which is a significant
shortcoming for a study that examines the effect of a pharmacologic
intervention.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.